Company / Capital Expenditures
Kiniksa Pharmaceuticals International, plc Capital Expenditures History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$1.6M
FY2025
5-year range
$105.0K / $3.2M
FY2021-FY2025
Trend
+466.1%
vs FY2024
Sector context
#100 of 194
Health Care
What the data says
Capital Expenditures changed +466% YoY in FY2025, a notable deviation from the 8-year average annual change of +1122%.
Based on SEC 10-K filings.
$2M in FY2025 with a 5-year CAGR of +40.8%.
Improved from $130,000 to $2M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- +146.3%
- 5-Year CAGR
- +40.8%
- 10-Year CAGR
- -
Sector benchmark
#100 of 194 in Health CareTop 52% of 194This company $1.6M Sector average $117.5M
▼
-98.7% below sector average
Key checks
Key Insights
- Kiniksa Pharmaceuticals International, plc's capital expenditures has grown for 3 consecutive years.
- 5-year CAGR of +40.8%, indicating consistent growth.
- In FY2025, capital expenditures increased 466.1% year-over-year.
- Ranks #100 out of 194 companies in the Health Care sector.
Company context
Key Data Points
- Negative profit margin: -10.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.6M | +466.1% |
| FY2024 | $277.0K | +113.1% |
| FY2023 | $130.0K | +23.8% |
| FY2022 | $105.0K | -96.7% |
| FY2021 | $3.2M | +1031.8% |
| FY2020 | $283.0K | -91.2% |
| FY2019 | $3.2M | -39.5% |
| FY2018 | $5.3M | +7566.7% |
| FY2017 | $69.0K | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026